The acquisition of Sanofi’s BluePrint drugs rarely enhances portfolio immunology
In an important move, she highlights her ambition to lead to rare illnesses and immunology, the French pharmaceutical giant Sanofi announced her plan to obtain US -based BluePrint medicines for up to $ 9.5 billion. The agreement was announced by a press release on the Sanofi website. It is the largest of a European health care company this year and will see Sanofi pay $ 129 per share in cash, an important premium that sent the plan stock to go to the premarket trading. BluePrint drugs, known for its specialty in the treatment of systemic mastocytosis, a rare blood disorder



